UBS Reaffirms Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)
UBS analyst Graham Doyle maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA yesterday. The company’s shares closed last Tuesday at €36.97.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Doyle is an analyst with an average return of -0.7% and a 54.00% success rate. Doyle covers the Healthcare sector, focusing on stocks such as ConvaTec, Fresenius Medical Care AG & Co. KGaA, and Straumann Holding AG.
In addition to UBS, Fresenius Medical Care AG & Co. KGaA also received a Sell from J.P. Morgan’s David Adlington in a report issued yesterday. However, on January 13, Kepler Capital maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (LSE: 0H9X).
Based on Fresenius Medical Care AG & Co. KGaA’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of €4.88 billion and a net profit of €274.8 million. In comparison, last year the company earned a revenue of €4.76 billion and had a net profit of €213.03 million
Read More on GB:0H9X:
Disclaimer & DisclosureReport an Issue
- Fresenius Medical to accelerate its share buyback program
- Fresenius Medical price target raised to $28 from $26 at Truist
- Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley
- Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds
- Fresenius Medical names Charles Hugh-Jones as Global Chief Medical Officer
